Singapore conglomerate known for the Tiger Balm healthcare brand, also holding large equity stakes in UOB and UOL Group.
Singapore conglomerate known for the Tiger Balm healthcare brand, also holding large equity stakes in UOB and UOL Group.
Tiger Balm pain-relief products are made at its own factory in Singapore and sold through pharmacies and retailers across Asia and beyond. Alongside, it holds a large investment portfolio, chiefly UOB and UOL shares, which gives dividend income and portfolio gains independent of the consumer business.
In one line: Singapore's Tiger Balm maker, also a large equity-investment holding company.
Moat: wide (brand, IP / patents). Tiger Balm is a globally recognized, century-old heritage brand with strong pricing power in its niche.
Headquarters: Singapore · Founded: 1926
Size Haw Par (H02.SI) is a Singapore Health Care company (Pharmaceuticals: Major) with a market value of $2.08B, the 47th largest of 184 Singapore companies the cockpit tracks. Shares closed at S$12.27 on 18 Nov 2026.
Performance Over six months the shares fell 25.3%, against +2.8% for the median peer and -4.6% for the Singapore market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue fell 13.2% over the last twelve months (peer median +10.7%); the operating margin is 30.4% (peer median 14.7%).
Valuation It trades at 11.9× forward earnings against a peer median of 24.4× (4th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -12 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.8 points below its cost of capital (5.2% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | S$220M | S$230M | S$245M | S$232M | S$182M |
| Revenue growth | — | -6% | +5% | +27% | — |
| Gross profit | S$122M | S$129M | S$134M | S$135M | S$98.6M |
| EBITDA | S$73.2M | S$75.8M | S$70.6M | S$71.4M | S$51.5M |
| Net income | S$229M | S$265M | S$228M | S$217M | S$148M |
| Free cash flow | S$225M | S$269M | S$234M | S$209M | S$129M |
| Capital expenditure | S$2.40M | S$2.12M | S$3.46M | S$7.77M | S$19.7M |
| Total debt | n/a | S$44.7M | S$36.8M | S$28.5M | S$29.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Haw Par H02.SI | $2.08B | -25% | -13% | 30% | 11.9× | 3.2% |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 24.2× | 3.7% |
| Haleon HLN.L | $39.6B | 0% | +1% | 23% | 16.4× | 5.2% |
| Rohto Pharmaceutical 4527.T | $3.87B | +8% | +7% | 12% | 16.5× | -2.8% |
| Yunnan Baiyao 000538.SZ | $15.0B | +11% | +5% | 11% | 18.3× | -0.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | H02.SI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.3% | +2.2% | 8th lowest of 21 |
| 6-month return | -25.3% | +2.8% | 2nd lowest of 21 |
| Distance from 52-week high | -32.8% | -23.5% | 6th lowest of 21 |
| Revenue growth (TTM) | -13.2% | +10.7% | lowest of 20 |
| Operating margin | 30.4% | 14.7% | 4th highest of 19 |
| Forward P/E | 11.9× | 24.4× | 4th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | 3.2% | 1.1% | 6th most demanding of 15 |
| Growth delivered (Del g) | +15.7% | +8.5% | 6th highest of 15 |
| Hurdle (Req g minus delivered) | -12.4 pp | -4.7 pp | 7th least demanding of 15 |
| ROIC minus cost of capital | -3.8 pp | +0.8 pp | 4th lowest of 19 |
| EV / EBITDA | 25.3× | 15.4× | 3rd most expensive of 10 |
| Net debt / EBITDA | -11.3× | 1.1× | least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Haw Par H02.SI | Singapore | $2.08B | -25% | -13% | 30% | 11.9× | 3.2% | +15.7% |
| InnoCare Pharma 688428.SS | China | $2.07B | -7% | +135% | 35% | 85.7× | -10.9% | +344.2% |
| PharmaResearch 214450.KS | South Korea | $2.10B | -24% | +29% | 37% | 15.4× | -11.0% | +37.6% |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.04B | +9% | +5% | 22% | 15.9× | -4.7% | +10.6% |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.03B | -3% | +9% | 14% | 25.9× | 5.1% | +6.4% |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.03B | +19% | -1% | 14% | 16.9× | 1.7% | +15.7% |
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.02B | -45% | 0% | -47% | n/a | n/a | n/a |
| Hanall Biopharma 009420.KS | South Korea | $2.01B | +12% | +5% | 3% | n/a | n/a | n/a |
| Eris Lifesciences ERIS.NS | India | $1.98B | 0% | +11% | 26% | 27.9× | 26.3% | +20.9% |
| Zhejiang Hisun Pharmaceutical 600267.SS | China | $2.19B | +14% | -7% | 15% | 15.0× | -9.7% | -1.5% |
| Tonghua Dongbao Pharmaceutical 600867.SS | China | $2.19B | -12% | +18% | n/a | 25.4× | 0.9% | +0.3% |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.20B | +39% | +20% | 12% | 25.0× | 26.7% | +6.5% |
| Biohaven BHVN | United States | $1.95B | +46% | n/a | n/a | n/a | n/a | n/a |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.95B | -14% | +11% | 6% | 44.6× | n/a | n/a |
| Harmony Biosciences HRMY | United States | $1.94B | +6% | +20% | 22% | 8.6× | -10.5% | +40.3% |
| Jinyu Bio-Technology 600201.SS | China | $1.93B | -21% | +22% | 10% | 59.0× | 23.4% | -2.5% |
| Tsumura & 4540.T | Japan | $1.93B | +6% | +13% | 18% | 10.4× | n/a | n/a |
| Grand Pharmaceutical 0512.HK | Hong Kong | $1.93B | -25% | +7% | 13% | 9.4× | 1.2% | +14.1% |
| Shandong Buchang Pharmaceuticals 603858.SS | China | $2.25B | -7% | +4% | 10% | n/a | -2.5% | -5.8% |
| Shilpa Medicare SHILPAMED.NS | India | $1.91B | +94% | +37% | 21% | 54.3× | n/a | n/a |
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 23.8× | 20.1% | +6.2% |